Event Program & Speakers

Event Program and Speaker Faculty

Day 1: Tuesday, August 16, 2016

11:00 am
Registration (until 5:00 pm)
-  Buck Institute Main Lobby
11:30 am
Lunch (until 1:00 pm)
-  Atrium
1:00 pm
Welcome
-  Drexler Auditorium
  • Mike KopeChief Executive OfficerSENS Research FoundationVIDEO
1:15 pm
Keynote: Pinchas Cohen
-  Drexler Auditorium
  • Pinchas CohenWilliam and Sylvia Kugel Dean in GerontologyUSC Davis School of GerontologyExecutive DirectorEthel Percy Andrus Gerontology CenterVIDEO
2:00 pm
Session 1: Prolonging Lifespan Through Accurate Detection And New Approaches To Prevention.
-  Drexler Auditorium
Numerous candidate therapies with the potential to prolong lifespan have been discovered. In combination with diagnostic and prognostic technologies, these have the potential to enhance treatment and prevention strategies for age related diseases, including oncology and neurodegenerative indications.
  • Aubrey de GreyChief Science OfficerSENS Research FoundationVIDEO
  • Judith CampisiProfessorBuck Institute for Research on AgingVIDEO
  • John JacksonAssociate ProfessorInstitute for Regenerative Medicine, Wake Forest School of MedicineVIDEO
  • Gordon LithgowProfessorBuck Institute for Research on AgingVIDEO
Panel Discussion Moderator:
  • Aubrey de GreyChief Science OfficerSENS Research Foundation
3:45 pm
Coffee Break
-  Atrium
4:00 pm
Project 21
-  Drexler Auditorium
  • Mike KopeChief Executive OfficerSENS Research FoundationVIDEO
  • Michael GreveFounder & CEOForever Healthy FoundationCEOKizoo Technology VenturesVIDEO
4:15 pm
Session 2: Identification And Optimization Of Synergies Between ‘Old’ And ‘New’ Biotech Funding Models
-  Drexler Auditorium
Increasing complexity in therapeutic approaches is creating unique risks, opportunities and uncertainties in the translation of technologies for the treatment of age related diseases. Therefore, leveraged technological and regulatory risk has stimulated the evolution of novel sources of biotech risk capital, including patient capital funds and venture philanthropy. Discussion will focus on developments in this novel funding platforms and synergies with classic investment strategies.
  • Brian KennedyPresident and CEOBuck Institute for Research on AgingVIDEO
  • Debra MillerPresident & CEOCureDuchenneVIDEO
  • Brock ReeveExecutive DirectorHarvard Stem Cell InstituteVIDEO
Panel Discussion Moderator:
  • Mike KopeChief Executive OfficerSENS Research FoundationVIDEO
6:00 pm
Reception / Poster Session and Dinner
-  Atrium

Day 2: Wednesday, August 17, 2016

7:00 am
Registration (until 1:00 pm)
-  Buck Institute Main Lobby
7:00 am
Continental Breakfast
-  Atrium
8:15 am
Session 3: Science Is Changing. The Tools And Technologies Required To Deliver Science Must Respond
-  Drexler Auditorium
The convergence of ‘big data’ science and increased demands for richer regulatory submissions to support product expedited approvals has driven step-change innovations in the development of tools and technologies to support all stages and scales of research. An evaluation of the changing demands of the research community and the response of tool providers will be provided, spanning laboratory techniques to small scale manufacturing by academic-clinical centres.
  • David BrindleyDirector of AlliancesSENS Research FoundationVIDEO
  • Eric RoosStrategic Alliances Leader, Cell TherapyThermo Fisher ScientificVIDEO
  • Jeanne LoringProfessorScripps Research InstituteVIDEO
Panel Discussion Moderator:
  • Kim BureDirector of Regenerative MedicineSartorius Stedim Biotech
10:00 am
Coffee Break
-  Atrium
10:15 am
Session 4: As Paths To Clinic Are Expedited, The Distinction Between Development And Manufacturing Is Becoming Increasingly Blurred
-  Drexler Auditorium
The extraordinary and welcome growth in interest in novel therapeutic platforms, including in cell based immunotherapies, has the potential to transform patient outcomes in a range of acute and chronic diseases. However, given the relative nascence of the underpinning science and high level of academic engagement, increased awareness of biomanufacturing strategies is critical to delivering on this promise.
  • Sean KevlahanChief Executive Officer and Co-founderQuad TechnologiesVIDEO
  • James BrownVice President, Corporate DevelopmentAldevronVIDEO
  • Alan MooreVice President and Commercial Chief for Biologics and Advanced TherapiesWuxi App TecVIDEO
Panel Discussion Moderator:
  • Eric RoosStrategic Alliances Leader, Cell TherapyThermo Fisher Scientific
12:00 pm
Lunch
-  Atrium
1:00 pm
Alliance 21
-  Drexler Auditorium
  • David BrindleyDirector of AlliancesSENS Research FoundationVIDEO
1:15 pm
Session 5: Regulating New Platforms In Fundamentally New Ways
-  Drexler Auditorium
Investors, patients and regulators are united in the potential for expedited regulatory paths – previously reserved for orphan diseases – to accelerate and expand patient access. Through a number of case studies, existing and future global regulatory initiatives will be reviewed, lead by those with first hand experience in their development and implementation. Advances in regulatory science will be essential in the fight against age related diseases.
Speakers:
  • Kenneth HarrisChief AdvisorCurasense AdvisorsVIDEO
  • Melissa WalkerPresident and Chief Technology OfficerGraematterVIDEO
  • Evan SnyderDirector, Center for Stem Cell and Regenerative Medicine/Core FacilitySanford Burnham Prebys Medical Discovery InstituteVIDEO
Panel Discussion Moderator:
  • David BrindleyDirector of AlliancesSENS Research Foundation
3:00 pm
Break
-  Atrium
3:15 pm
Session 6: The End User Is The Patient... And The Clinician
-  Drexler Auditorium
Historically, the scope of the engagement of clinicians in the adoption of new therapies was limited to counselling patients and prescribing expanding corners of the pharmacopeia. Stratified medicines have led to the need for clinicians to deepen their patient engagement strategies, and embark upon the development of entirely new infrastructure to accommodate patient specific therapies and enhanced pharmacovigilance demands.
  • Bernard MunosSenior FellowFasterCuresFounderInnoThinkVIDEO
  • Mark ZimmermanVice President, Strategy and Business DevelopmentViacyteVIDEO
  • Khalid ShahDirector, Stem Cell Therapeutics and Imaging ProgramMassachusetts General HospitalAssociate ProfessorHarvard Medical SchoolVIDEO
Panel Discussion Moderator:
  • Brock ReeveExecutive DirectorHarvard Stem Cell InstituteVIDEO
5:00 pm
Concluding Remarks
-  Drexler Auditorium
  • Mike KopeChief Executive OfficerSENS Research FoundationVIDEO
5:30 pm
Reception / Poster Session and Dinner
-  Atrium
 

Speaker Faculty

Keynote Speaker

Pinchas Cohen, M.D.
Dean, USC Davis School of Gerontology
Executive Director, Ethel Percy Andrus Gerontology Center
William and Sylvia Kugel Dean’s Chair in Gerontology
View Bio

Dr. Cohen trained in Stanford and held his first faculty position at the University of Pennsylvania from 1992 to 1999. Until 2012, he was a professor and Vice Chair for Research at the Mattel Children's Hospital at UCLA, as well as the Co-Director of the UCSD/UCLA Diabetes Research Center.

He received numerous awards for his research, including a National Institute of Aging "EUREKA"-Award, the NIH-Director-Transformative RO1-Grant, and the Glenn Award for Research in Biological Mechanisms of Aging.

He holds several patents for novel peptides and is the Cofounder of CohBar, a biotechnology company developing mitochondrial peptides for diseases of aging. Dr. Cohen has published over 300 papers in top scientific journals focusing on aging, diabetes, Alzheimer's, cancer, growth hormone/IGF-biology and the emerging science of mitochondrial-derived peptides, which he pioneered.

Dr. Cohen is president of the Growth Hormone Society and served on the Endocrine Society Steering Committee. He sits on multiple NIH study sections and on several editorial boards as well as on the American Federation of Aging Research Board.

Dr. Cohen is leading several new initiatives at the USC Davis School, including the development of a center for digital aging, and a major focus on the creation of tools for "personalized aging", an approach he has been spearheading for the purpose of garnering the latest technologies such as genomics towards individualizing healthy aging strategies, that has been featured in the Milken Global Conference and in the Bloomberg Longevity Economy Conference.

Dr. Cohen’s Laboratory focuses on unraveling processes related to aging, diabetes, neurodegeneration, and cancer. In particular, they focus on the emerging science of mitochondrial-derived peptides including, 1) humanin, a peptide encoded from the mt-16S-rRNA which is a novel, centrally acting, insulin sensitizer and metaboloprotective factor representing a new therapeutic and diagnostic target in aging, diabetes and related disease and 2) MOTS-c, a second peptide encoded from a small ORF in the 12S region of the mitochondrial chromosome, that has potent anti-diabetes and anti-obesity effect, acting as an exercise-mimetic.

Close

Faculty

David Brindley

Director of Alliances

SENS Research Foundation

View Bio

David is an international thought-leader in healthcare risk management, with a particular interest in regenerative medicines. His multi-disciplinary research seeks to evaluate and develop systematic, rigorous and transparent risk management tools supporting the translation of life-science innovations into commercially viable products and services.

In all cases, David strives to conduct research that is both academically rigorous and commercially practicable. His expertise spans the ‘Valley of Death,’ encompassing regulation, engineering and finance.

At the SENS Research Foundation David leads all aspects of the Alliance Programs.  He currently manages the CTSCC (CASMI Translational Stem Cell Consortium) program, the Alliance program and the development of a Rejuvenation Biotechnology Translational Consortium (RBTC).  Within CTSCC, David leads all research activities pertaining to risk. David’s work can be found in a range of high impact journals including Nature, Nature Biotechnology, Nature Medicine and Cell Stem Cell. Additionally, David serves as an Editorial Board member for a range of international academic and industrial journals. David also produces a popular blog, Cell Therapy Industry 2027, with the Centre for the Commercialisation of Regenerative Medicine.

David is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. David has successfully passed the Charted Analyst in Alternative Investments (CAIA) Level 1 examination. David indulges his entrepreneurial spirit through his consultancy, Translation Ventures Ltd, providing timely and pragmatic advice and training to a range of stakeholders in healthcare translation, including the venture capital community. Additionally, David is a strategic advisor to a number of SMEs pursuing excellence in healthcare risk management solutions, including Spoonful of Sugar and Oxford Risk.

David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honors and his Masters, investigating the commercialisation of regenerative therapies, jointly at the Harvard Stem Cell Institute and Harvard Business School (Prof. William Sahlman). David received a DPhil (PhD) in Musculoskeletal Sciences at the University of Oxford.

James Brown

Vice President, Corporate Development

Aldevron

View Bio

James Brown, Ph.D., joined Aldevron in 2015 and serves as Vice President of Corporate Development. His responsibilities include developing and implementing strategies for expanding Aldevron's DNA, mRNA, antibody, and protein products and production services. Prior to joining Aldevron Dr. Brown was Vice President, Technical Operations at REGENXBIO Inc., a gene therapy company. In this role he was responsible for contract manufacturing, vendor management, operations, quality assurance, and biological reagent sales. Prior to REGENXBIO Dr. Brown was Director of Relationship Management at MedImmune, AstraZeneca's global biological development arm. His responsibilities there included management of information technologies and services for research and development. Earlier in his career, Dr. Brown served in roles of increasing responsibility in information technology and quality assurance at Meso Scale Discovery and IGEN International, Inc. Dr. Brown holds a Ph.D. in Chemistry from Stanford University and a B.S. in Chemistry from Butler University.

Kim Bure

Director of Regenerative Medicine

Sartorius Stedim Biotech

View Bio

Kim is the Director of Regenerative Medicine at Sartorius Stedim Biotech, which acquired her former employer, TAP Biosystems, in late 2013. She is passionate about translating automated cGMP biomanufacturing innovation into solutions for emerging markets. Over her seven year career at TAP, while partnering with clients in both biologics and drug discovery around process robustness and comparability, she has built a strong foundation from which to address the numerous challenges facing cellular therapeutic bioprocessing. Now at SSB, her focus has been repurposing and refining existing technologies for broader applications. Presently, Kim is the Industrial Lead for the CASMI Translational Stem Cell Consortium.

Previous positions advocating novel technology products at Invitrogen (now Life Technologies), Molecular Devices and Alltech (now W.R. Grace), have further equipped her with a broad knowledge of the life science marketplace and depth with respect to the hurdles encountered by early stage markets. Kim earned a degree in Chemistry from Northwestern University and remains a staunch supporter of the resultant benefits provided by rigorous system and process controls. When not traveling the world, Kim is a keen horticulturalist with true appreciation of floriculture and viniculture, most often paired with her avid affection for fast cars.

Judith Campisi

Professor

Buck Institute for Research on Aging

View Bio

Judith Campisi received a PhD in Biochemistry from the State University of New York at Stony Brook, and postdoctoral training in cell cycle regulation and cancer at the Dana-Farber Cancer Institute and Harvard Medical School. As an Assistant Professor at the Boston University Medical School, she began to focus her laboratory on role of cellular senescence in suppressing the development of cancer, but soon became convinced that senescent cells also contributed to aging. She left Boston University as an Associate Professor to accept a Senior Scientist position at the Lawrence Berkeley National Laboratory in 1991. In 2002, she established a laboratory at the Buck Institute for Age Research, where she is a Professor. At both institutions, Campisi established a broad program to understand various aspects of aging, with an emphasis on the interface between cancer and aging. Her laboratory made several pioneering discoveries in these areas. Her research continues to challenge and alter existing paradigms. In recognition of the quality of her research and leadership, Campisi received numerous awards, including two MERIT awards from the US National Institute on Aging, awards from the AlliedSignal Corporation, Gerontological Society of America and American Federation for Aging Research, and the Longevity prize from the IPSEN Foundation. She serves on numerous national and international editorial and advisory boards.

Aubrey de Grey

Chief Science Officer

SENS Research Foundation

View Bio

Dr. de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

Michael Greve

Founder & CEO

Forever Healthy Foundation

CEO
Kizoo Technology Ventures
View Bio

Michael Greve is the founder of numerous successful Internet companies including Web.de and LastMinute.de. He is currently the CEO of Kizoo Technology Ventures and the founder and CEO of the Forever Healthy Foundation. The Forever Healthy Foundation is a private nonprofit initiative whose mission is to enable people to vastly extend their healthy lifespans and be part of the first generation to cure aging. In order to accelerate the development of therapies to get aging under full medical control, the Forever Healthy Foundation directly supports cutting edge research aimed at the molecular and cellular repair of damage caused by the aging process. Visit www.forever-healthy.org and www.kizoo.com.

Kenneth Harris

Chief Advisor

Curasense Advisors

View Bio

Biography pending.

John Jackson

Associate Professor

Institute for Regenerative Medicine, Wake Forest School of Medicine

View Bio

Dr. John D. Jackson is an Associate Professor in the Institute for Regenerative Medicine at Wake Forest School of Medicine, Winston Salem, NC. He received his Ph.D. degree in Medical Sciences (Experimental Hematology) from the University of Nebraska Medical Center, Omaha, NE. He received post-doctoral training in the laboratory of Dr. Donna Rennick at DNAX Research Institute, Palo Alto, CA. At DNAX Research Institute, Dr. Jackson was involved in research directed to the study of the role of cytokines on the regulation of hematopoietic and immune systems. In 1990, Dr. Jackson joined the Department of Pathology and Microbiology at the University of Nebraska Medical Center, Omaha, NE as an Assistant Professor. He was also appointed Technical Director of the Cell Processing Laboratory at the University of Nebraska Medical Center which provided support for the bone marrow transplantation program. His research focus during this time was directed toward the effects of cytokines and other agents on hematopoietic mobilization for transplantation as well as hematopoietic and immunological recovery following transplantation. In 2010, Dr. Jackson moved to Wake Forest School of Medicine and serves as an Associate Professor in the Institute for Regenerative Medicine. His research interests have broadened to include tissue engineering of tissues and organs including skin, thymus, inner ear, kidney, and ovary.

Brian Kennedy

President and CEO

Buck Institute for Research on Aging

View Bio

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and is a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing and treating age-related conditions. He leads a team of 23 principal investigators at the Buck Institute – all of whom are involved in interdisciplinary research aimed at extending healthspan, the healthy years of life.

The inventor on several patents, Dr. Kennedy is co-founder of two U.S. companies aimed at developing treatments for age-related chronic disease. He is actively involved in aging research in the Pacific Rim, which features the largest elderly population in the world. He is a visiting professor at the Aging Research Institute at Guangdong Medical College in China. In the past year he lectured in Korea, Russia, China, Chile, Austria, Italy and the United Kingdom. In conjunction with the University of Southern California, he also launched the nation’s first PhD Program in the Biology of Aging.

Dr. Kennedy has published more than 130 manuscripts in prestigious journals including Science and Nature and has been quoted in The Wall Street Journal, The New York Times and The Boston Globe, among others. He is co-Editor-in Chief of Aging Cell and serves as a consultant for biotech and pharmaceutical companies. His own research has led to the discovery of Sirtuins and the mTOR pathway as key regulators of aging, with current studies involving an intensive focus that is unusual in the field – his work seeks to move discoveries from simple organisms into mammalian animal models as quickly as possible in order to develop new approaches to alleviate age-associated diseases in humans.

Sean Kevlahan

Chief Executive Officer and Co-founder

Quad Technologies

View Bio

Sean Kevlahan, is a product driven entrepreneur in the Life Science sector and specialist in cell biology. Dr. Kevlahan holds a B.S in biochemistry from Hofstra University and received his Ph.D. in chemical engineering from Northeastern University. Sean co-founded Quad Technologies, which has developed a novel chemistry called Quickgel to enable capture and release cells viably off of variety of different substrates. Quad is actively pursuing the cellular immunotherapy workflow with Quickgel by enrichment of T-cells, subsequent T-cell activation, and immediate viable decoupling of the cell from a substrate. We believe that providing an upfront release mechanism from magnetic particles or other substrates can save a significant amount of manufacturing time and decrease COGS of the CAR-T workflow.

Mike Kope

Chief Executive Officer

SENS Research Foundation

View Bio

Mr. Kope received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; as Director of Corporate Development for Aviron, and for MedImmune, Inc.; and as CEO and officer of a number of start-ups in the biotechnology space. He specializes in business development and consulting, and is widely experienced with biotechnology organizations. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.

Gordon Lithgow

Professor

Buck Institute for Research on Aging

View Bio

Dr. Lithgow sheds light on the mechanisms of aging by identifying agents that extend lifespan or prevent age-related disease. He has discovered a range of factors that can lengthen life in the microscopic worm Caenorhabditis elegans, and he applies these findings to studies in human cell cultures. Much evidence points to stress contributing to a breakdown in the ability to maintain optimal molecular stability resulting in aging and disease. Certain life-extending agents help C. elegans respond to lifelong stress by remodeling the natural stress fighting cellular mechanisms, the Lithgow lab has found. For example, long-lived mutants of C. elegans are very stress resistant as a result of elevated levels of "heat shock proteins." Heat shock proteins promote longevity probably by preventing a loss of protein balance. Long-lived mutant strains are also resistant to heavy metals, so the Lithgow lab is now studying the relationship between longevity and "metallostasis".

The Lithgow lab has discovered that certain cell proteins capable of extending life can also be closely involved in disease prevention. But when proteins play such dual roles, they may sometimes make tradeoffs that affect the fate of the organism. Dr. Lithgow is studying genetic variations in "checkpoint proteins" that may create a trade-off between the rate of aging and incidence of cancer.

The Lithgow lab has made seminal discoveries in the use of pharmacological agents to intervene in aging processes, such as antioxidants that protect cells against damage from unstable chemicals called free radicals. More recently, his lab have uncovered compounds that act as "stress response mimetics" that maintain protein balance and stability. These compounds suppress pathology associated with Alzheimer’s disease. The lab continues to undertake screens for chemical compounds that slow aging and extend healthspan.

Dr. Lithgow received his PhD in Genetics from the University of Glasgow, Scotland. He completed postdoctoral training at the Institute for Behavioral Genetics at the University of Colorado, Boulder. Dr. Lithgow was a Senior Lecturer in Molecular Gerontology at the School of Biological Sciences at the University of Manchester in England before coming to the Buck Institute in 2001. He is the Principal Investigator and Director of the Buck Institute’s Interdisciplinary Research Consortium on Geroscience. He is also the Principal Investigator of the Larry L. Hillblom Network on the Chemical Biology of Aging, and is the Coordinator of the Hillblom Center for the Biology of Aging Support Award.

Jeanne Loring

Professor

Scripps Research Institute

View Bio

Jeanne Loring, Ph.D., is a Professor and the founding Director of the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla. Her research team focuses on large-scale analysis of genomics and epigenetics of human pluripotent stem cells (hPSCs) and their derivatives, in order to ensure the quality and safety of these cells for clinical use. The team's translational projects include development of cell therapies for Parkinson’s disease, multiple sclerosis, and Alzheimer disease, and epigenetic modeling of autism. The team is also producing an ethnically diverse library of iPSC (induced pluripotent stem cell) lines for use in pharmaceutical screening. In addition, her lab is developing a "zoo" of induced pluripotent stem cells from endangered species to aid in their conservation. Dr. Loring is committed to educating both scientists and the public. She has trained more than 400 scientists over the last 10 years in intensive laboratory courses in human ES and iPSC biology, and is author of a comprehensive laboratory manual on human pluripotent stem cells ("Human Stem Cell Manual: a Laboratory Guide, in second edition, 2012). She is frequently quoted in major newspapers, and gives numerous public lectures and interviews to inform the public about biological and societal issues associated with stem cell research, including the ethics of stem cell generation and clinical use, the legal implications of stem cell patents, and public education about the dangers of unregulated stem cell treatments (“stem cell tourism”). Dr. Loring serves on both bioethics and scientific advisory boards.

Debra Miller

President & CEO

CureDuchenne

View Bio

Debra Miller co-founded CureDuchenne in 2003 with her husband, Paul, after their only son was diagnosed with Duchenne. Miller relies on her extensive background in sales and marketing to lead CureDuchenne.

Her role includes overseeing all operations, research and financial resources as well as serving as the primary liaison to the Board of Directors. She is the decision maker, leader and manager in carrying out the mission of the organization. She also works closely with the Scientific Board of Advisors in designing and implementing the medical research strategic plan.

Miller earned a Bachelor of Arts in Communication Studies from the University of California Los Angeles. Prior to CureDuchenne, she had a career in publishing with positions in advertising sales and was an independent stock trader.

Alan Moore

Vice President and Commercial Chief for Biologics and Advanced Therapies

Wuxi App Tec

View Bio

Alan Moore is responsible for commercial activities supporting biopharmaceutical products and advanced therapies such as cell and genetic therapies. Previously he oversaw cGMP-compliant contract manufacturing of innovative cell and gene therapies for WuXi AppTec, Inc. in WuXi’s Philadelphia-based manufacturing sites, as well as supported strategic biopharmaceutical clients. He held positions of increasing responsibility over a 16 year period at BioReliance Corp. (Microbiological Associates) leading to Director of Business Development, after previously serving as Director of the firm’s Biotechnology Services Division. He served as President of Genzyme Transgenics Washington Laboratories, and Senior Regulatory Coordinator for Genzyme Corporation supporting products such as Carticel®, Epicel®, Cerezyme®, and later as Vice President of Biopharmaceutical Development Services at Genzyme Corporation’s Rockville, MD facility which provided contract development, manufacturing and testing for biological products. Prior to joining WuXi AppTec, Mr. Moore served as Executive Vice President and Chief Business Officer at Althea Technologies (San Diego, CA), a leading provider of innovative technologies along with manufacturing and aseptic fill and finish services. Mr. Moore has presented on biopharmaceutical, cell and gene therapy development and safety to the U.S. FDA Center for Biologics Evaluation and Research, various U.S. FDA Advisory Committees, Health Protection Branch, Drugs Directorate (Canada), Therapeutic Goods Administration (Australia), Japan Health Science Council (Ministry of Health), and the U.K. Xenotransplantation Interim Regulatory Authority (UKXIRA). He has also served as a member of U.S./Japan Bilateral Forum on the Harmonization of Biotechnology Regulations (United States Department of Commerce– Predecessor to ICH), and a delegate to the International Bioindustry Forum (US/Japan/EU), The President's Council on Competitiveness for Streamlining Federal Regulation of Biotechnology Products at The White House.

Bernard Munos

Senior Fellow

FasterCures

Founder
InnoThink
View Bio

Bernard Munos is a Senior Fellow at FasterCures, a Center of the Milken Institute. He was previously an advisor for corporate strategy at Eli Lilly. His research, which focuses on pharmaceutical innovation has been published in Nature and Science, and profiled by Forbes magazine. The popular industry newsletter FiercePharma has named him one of the 25 most influential people in biopharma.

Munos advises organizations on being better innovators. He serves on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS); is a member of the National Academy of Medicine's Forum on Drug R&D and Translation; an Advisor to the journal Science Translational Medicine; and an Advisor to or Board member of a dozen companies or publicly-financed research organizations.

Munos received his MBA from Stanford University, and holds other graduate degrees from UC-Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He blogs for Forbes and FasterCures.

Brock Reeve

Executive Director

Harvard Stem Cell Institute

View Bio

Brock Reeve is Executive Director of the Harvard Stem Cell Institute. In partnership with the Faculty Directors, he has overall responsibility for the operations and strategy of the Institute whose mission is to use stem cells, both as tools and as therapies, to understand and treat the root causes of leading degenerative diseases. HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. Under the leadership of the Executive Committee, HSCI invests in scientific research and its faculty has grown to include over 300 Principal and Affiliated members. The Institute is engaged with several leading pharmaceutical companies and foundations in joint research projects and its faculty have founded several stem cell-related start-up companies and serve on leading Scientific Advisory Boards. Brock came to this role from the commercial sector with extensive experience in both management consulting and operations for technology-based companies, with a focus on life sciences. Brock received a BA and MPhil from Yale University and an MBA from Harvard Business School.

Eric Roos

Strategic Alliances Leader, Cell Therapy

Thermo Fisher Scientific

View Bio

Biography pending.

Khalid Shah

Director, Stem Cell Therapeutics and Imaging Program

Massachusetts General Hospital

Associate Professor
Harvard Medical School
View Bio

Dr. Shah is an Associate Professor at Harvard Medical School. He is also the Director of the Stem Cell Therapeutics and Imaging program at MGH and a Principal Faculty at Harvard Stem Cell Institute in Boston. His laboratory focuses on developing therapeutic stem cells for receptor targeted therapies for cancer and testing their efficacy in clinically relevant mouse tumor models. In recent years, Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology, validating the use of therapeutic stem cells alone and in combination with clinically approved drugs for cancer therapy.

Recently, Dr. Shah's work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.

Evan Snyder

Professor/Director, Center for Stem Cells and Regenerative Medicine

Sanford Burnham Prebys Medical Discovery Institute

View Bio

Evan Snyder earned his M.D. and his Ph.D. in neuroscience from the University of Pennsylvania in 1980. He completed residencies in pediatrics and neurology at Children's Hospital-Boston, Harvard Medical School and postdoctoral research at Harvard Medical School. In 1992, Dr. Snyder was appointed an instructor in neurology at Harvard Medical School and was promoted to assistant professor in 1996. He is regarded as one of the fathers of the stem cell field, having identified over 2 decades ago that cells that came to be called stem cells were a source of neural plasticity. He was the first to demonstrate that non-hematopoietic stem cells could mediate cell and gene replacement, home to injury, and perform protective, trophic, pro-regenerative, and anti-inflammatory actions. He was also the first to isolate human neural stem cells. In 2003, after 23 years at Harvard, Dr. Snyder was recruited to Sanford Burnham Prebys Medical Discovery Institute as professor and director of the Stem Cells and Regeneration Center and Core Facility.

Melissa Walker

President and Chief Technology Officer

Graematter

View Bio
 
Melissa Walker is the president, CTO, and founder of Graematter, Inc., a regulatory intelligence firm focused on using Open Data to simplify the complex regulatory processes needed to get medical products to patients. Prior to founding the Company, she served in various senior level positions in both public and private firms, leading the regulatory, quality systems, and clinical research functions, including submissions, complaint-handling, regulatory compliance, clinical research, and healthcare compliance. An inventor, she has been awarded two patents for a web-based regulatory intelligence system that serve as the key technology underpinning Graematter.
 
With 30 years of experience as a regulatory professional, Ms. Walker brings a depth of knowledge and experience of the regulatory profession on a global basis. She has managed or provided consulting expertise in this field to a number of medical product start-up companies in a variety of therapeutic areas. She has also served as a director and as Chairman of the Board of the Regulatory Affairs Professionals Society; as an industry representative on the FDA Medical Devices Dispute Resolution Panel; and as an expert witness.
 
Ms. Walker has been honored as a Fellow of the Regulatory Affairs Professionals Society and has earned RAC certification from the Regulatory Affairs Certification Board. She has an M.S. degree in Zoology and a B.S. degree in Biology and Animal Science from East Texas State University (now Texas A&M Commerce). She is an adjunct instructor at Washington University in St Louis, teaching in the Clinical Research Management degree program.
Mark Zimmerman

Vice President, Strategy and Business Development

Viacyte

View Bio

Mark Zimmerman received his bachelors in Biology from Syracuse University and his masters and doctorate in Biomedical Engineering from Rutgers University. Mark joined UMD-New Jersey Medical School as an Assistant Professor in 1986 and left in 1996 as an Associate Professor of Surgery with tenure. His research interests spanned musculoskeletal tissue engineering, sports medicine, trauma, and spine biomechanics and biomaterials.

Mark joined Johnson and Johnson in 1997 as a principal scientist/group leader and transitioned into regenerative medicine projects related to orthopaedic surgery, wound healing, vascular biology, and diabetes. Mark was appointed executive director of a Lifescan incubator, BetaLogics, in July 2002. BetaLogics transitioned to a Johnson and Johnson Internal Venture in 2004. The mission of BetaLogics was to discover and develop a cellular product to treat diabetes. Mark was appointed Venture Leader/Vice President of BetaLogics, a business unit of Janssen R&D LLC in 2009.

Janssen completed a business transaction with ViaCyte in 2015 and merged the assets of BetaLogics into ViaCyte. Mark is currently seconded to ViaCyte and serves as the Vice President of Strategy and Business Development.

Mark is a fellow in the American Institute of Mechanical and Biomedical Engineers, a member of numerous societies (Tissue Engineering Society, International Society for Stem Cell Research, the International Society for Cell Therapy, the American Diabetes Association, the American Society of Mechanical Engineers, the Biomaterials Society). Mark also serves on the Cell and Gene Therapy CATAPULT industrial Advisory Board (a UK govt. funded organization supporting the commercialization of Cell and Gene Therapy). Mark has authored 44 peer-reviewed publications, 10 book chapters, 136 abstracts and is an inventor on 24 patents.